Table 1.

SGLT-2 inhibitor and GLP-1 receptor agonist glucose lowering CVOTs in diabetes

Trial	Primary outcome	CVD death	Myocardial infarction	Stroke	All-cause mortality	HHF	Mean reduction in HbA1c (%)	Effect of reduced glycemia on MACE
GLP-1 RAs
LEADER	P=0.01	P=0.007	P=0.046	NS	P=0.02	NS	−0.40	NA or NS
SUSTAIN-6	P=0.02	NS	NS	P=0.04	NS	NS	−1.3	NS
ELIXA	NS	NS	NS	NS	NS	NS	−0.27	NS
EXSCEL	P=0.06	NS	NS	NS	NS	NS	−0.53	NA or NS
REWIND	P=0.02	NS	NS	P=0.01	NS	NS	−0.61	NA or NS
SGLT2 Inhibitors
EMPA-REG	P=0.04	P<0.001	NS	HS	P<0.001	P<0.001	−0.42	NS
CANVAS	P=0.02	NS	NS	NS	NS	P=0.002	−0.58	NS
CREDENCE	P=0.01	NS	NS	NS	NS	P=0.001	−0.25	NA
DECLARE-58	NS	NS	NS	NS	NS	P=0.005	−0.42	NA or NS
VERTIS	NS	NS	NS	NS	NS	P=0.006	−0.50	NA or NS

HHF, hospitalization for heart failure; NS, not significant; NA, not assessed or published

LEADER (Marso et al., 2016b); SUSTAIN-6 (Marso et al., 2016a); ELIXA (Pfeffer et al., 2015); EXSCEL (Holman et al., 2017); REWIND (Gerstein et al., 2019); EMPA-REG (Inzucchi et al., 2018; Zinman et al., 2015); CANVAS (Neal et al., 2017); CREDENCE (Cannon et al., 2020a; Mahaffey et al., 2019; Perkovic et al., 2019); DECLARE-58 (Wiviott et al., 2019); VERTIS (Cannon et al., 2020b)